Clinical Trial Update: Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial assessing selumetinib sulfate in locally advanced or metastatic pancreatic cancer with KRAS G12R mutations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Selumetinib Sulfate (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2021-01-11